RenukaGeraMD

Pediatric Hematology & Oncology • Lansing, MI

Professor, Pediatrics & Human Development, Michigan State University, College of Human Medicine Division Chief MSU Adolescent and Pediatric Hematology and Oncology Department of Pediatrics and Human development College of Human Medicine Michigan State University East Lansing MI 48824

Join to view full profile

Dr. Gera is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gera's full profile

Already have an account?

Office
1200 East Michigan Avenue, Ste 145
Lansing, MI 48912
Phone+1 517-364-5440

Fax+1 517-364-5413

Education & Training

University of Michigan Health - Sparrow/Michigan State UniversityResidency, Pediatrics, 1979 - 1982
Michigan State UniversityBoard Certified Pediatrics, 1979 - 1982
Gajra Raja Medical CollegeClass of 1974

Certifications & Licensure

MI State Medical License 1982 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
ACTIVE_NOT_RECRUITING
PHASE3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
ACTIVE_NOT_RECRUITING
PHASE3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Join now to see all

Publications & Presentations

PubMed

24 citations
Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses
Zoheb B. Kazi, Sean N. Prater, Joyce A. Kobori, David Viskochil, Carrie Bailey
JCI Insight. 2016-07-21
71 citations
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease
Suhrad G. Banugaria, Sean N. Prater, Judeth K. McGann, Jonathan D. Feldman, Jesse A. Tannenbaum
Genetics in Medicine. 2013-02-01
1 citations
Co-occurrence of Chiari malformations and sickle cell disease-a diagnostic dilemma: a report of 4 cases and review of literature.
Satheesh Chonat, Elna Saah, Renuka Gera, A. B. Scott-Emuakpor, Roshni Kulkarni
Journal of Pediatric Hematology/oncology. 2011-12-01